Panbela Announces Closing of Approximately $9.0 Million Public Offering

2 months ago

MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of…

Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024

2 months ago

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11…

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

2 months ago

MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and…

Opthea Strengthens Team with Key Clinical and Regulatory Hires

2 months ago

Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track…

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

2 months ago

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage…

Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

2 months ago

DMPK Lab at Sai Life Sciences DMPK Lab at Sai Life Sciences HYDERABAD, India, Feb. 01, 2024 (GLOBE NEWSWIRE) --…

HUTCHMED to Announce 2023 Final Results

2 months ago

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:…

EnteroBiotix Strengthens its Executive Team, Appoints COO and CFO

2 months ago

GLASGOW, Scotland, Feb. 01, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage biopharmaceutical company with the premier platform…

Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation

2 months ago

Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation…

Legacy Novozymes delivers solid last full-year results

2 months ago

Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales…